PAVax SIGNED
A training network for the design of new synthetic carbohydrate-based vaccines to combat antibiotic resistant Pseudomonas aeruginosa
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0PAVax project word cloud
Explore the words cloud of the PAVax project. It provides you a very rough idea of what is the project "PAVax" about.
Project "PAVax" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITEIT LEIDEN
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Total cost | 1˙054˙239 € |
| EC max contribution | 1˙054˙239 € (100%) |
| Programme |
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers) |
| Code Call | H2020-MSCA-ITN-2019 |
| Funding Scheme | MSCA-ITN-EID |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-03-01 to 2024-02-29 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITEIT LEIDEN | NL (LEIDEN) | coordinator | 531˙239.00 |
| 2 | GLAXOSMITHKLINE VACCINES SRL | IT (SIENA) | participant | 522˙999.00 |
Map
Project objective
PAVax is a network that will train 4 early-stage researchers (ESRs) on the conception of new synthetic vaccines to combat the antibiotic resistant bacterium Pseudomionas aeruginosa (PA), for which there currently is no adequate vaccine available. This consortium will explore and exploit the use of PA-exopolysaccharides that play a key role in biofilm formation that protects the bacterium from its environment: alginate, Psl and Pel. We will exploit these saccharides to generate novel vaccines targeting these exposed polysaccharides. Next to the isolation of these polysaccharides from the bacteria, we will employ synthetic chemistry to deliver well-defined fragments of these polysaccharides. These will be used to map the interactions of the saccharides with antibodies to inform on the structure of the optimal epitope. We will conjugate the (synthetic) fragments to newly discovered PA proteins to generate conjugate vaccines targeting multiple PA entities. The consortium is formed by an academic partner, Leiden University (NL) and an industrial partner, GSK Vaccines, Siena (IT), harnessing the complementary expertise of both partners to achieve the ambitious goals set. The close collaboration between the two partners will ensure training of the ESRs at the highest level and best synergy possible. The ESRs will receive intersectorial, international and interdisciplinary training in (synthetic) carbohydrate chemistry, vaccine design, protein chemistry and conjugation, biophysical interaction studies, and immunology. With the ever-growing awareness of the importance of carbohydrates in health and disease, and the continuous threat of multidrug resistant bacteria, the skill set acquired by the ESRs will prepare them to face the major scientific and societal challenges ahead and become important players in academic or industrial research in the future
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PAVAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PAVAX" are provided by the European Opendata Portal: CORDIS opendata.